Skip to content
OpenCapital
Get started

Gyre Therapeutics, Inc. GYRE Business Sale Proceeds

Business Sale Proceeds at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$200M—

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10—

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%—

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0×0.0×
Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfProductiveAssets.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s business sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s business sale proceeds?
Gyre Therapeutics, Inc. (GYRE) reported business sale proceeds of $6K in Q1 2026.
How has Gyre Therapeutics, Inc.'s business sale proceeds changed year-over-year?
Gyre Therapeutics, Inc.'s business sale proceeds increased by 500.0% year-over-year, from $1K to $6K.
What does business sale proceeds mean?
Cash received from divesting business units or subsidiaries, net of cash in the disposed entity.